This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
In recent years, the adoption of advanced treatments in inflammatory bowel disease has evolved. Oral products have captured a significant share in ulcerative colitis, while Skyrizi, a 3rd generation biologic, has gained share in Crohn’s Disease. Despite these newer entrants, 1st generation biologics maintain significant patient share in both diseases.
In April 2024, CRA’s Life Sciences Practice hosted a dinner and interactive roundtable discussion on “Payer Value Demonstration – The Evolving Role of HEOR,”...
Charles River Associates has previously assessed the implications of proposals to implement international reference pricing in the US and found they would...
